Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

TCTMD’s Top 10 Most Popular Stories for May 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

June 01, 2017

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

TCTMD’s Top 10 Most Popular Stories for February 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

March 01, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.